Nazmul Hassan said, “The completion of this deal is a major milestone for us. We have a clear strategy to continue our diversification and expansion, strengthening our position as a market-leading pharma company in Bangladesh.
“We look forward to welcoming over 800 skilled and diligent Sanofi Bangladesh employees to our existing workforce. As an enlarged group, we are excited to continue our growth trajectory by delivering affordable treatments and breakthrough therapies in our growing domestic market,” he added.
Sanofi Bangladesh, part of global biopharmaceutical company Sanofi SA, started operating in the country in 1958 as part of British chemical company May & Baker.
Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed Sanofi Bangladesh in 2013.
Sanofi’s manufacturing facility is located near Beximco in Tongi and the company is producing around 100 branded generic products – mainly for the local market. It produces a significant quantity of medicines for cardiology, diabetes, oncology, and dermatology conditions.
The company also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports.